Report: AppSec Teams Stuck in Catch-Up Cycle Due to Massive Cloud-Native Enablement Gap, Unable to Keep Up with Agile Developer Pace
85% of AppSec pros say ability to differentiate between real risks and noise is critical,…
Month: May 2023
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage…
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage…
Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity
UB-VV200 preclinical data highlight successful generation of TagCAR T cells, which demonstrate dose-dependent anti-tumor activity…
Umoja Biopharma Presents New Preclinical Data at the American Society of Gene and Cell Therapy 26th Annual Meeting Demonstrating Potent In Vivo CAR T Cell Generation and Durable Anti-Tumor Activity
UB-VV200 preclinical data highlight successful generation of TagCAR T cells, which demonstrate dose-dependent anti-tumor activity…
LAPIX Therapeutics Inc. Announces the Issuance of U.S. Patent for LPX-TI641, Its First-in-Class, Orally Administered Tim3/4 Agonist for Treg Expansion to Treat Autoimmune Diseases
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) — LAPIX Therapeutics, Inc. (“LAPIX”), a biopharma company focused…
LAPIX Therapeutics Inc. Announces the Issuance of U.S. Patent for LPX-TI641, Its First-in-Class, Orally Administered Tim3/4 Agonist for Treg Expansion to Treat Autoimmune Diseases
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) — LAPIX Therapeutics, Inc. (“LAPIX”), a biopharma company focused…
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) — Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today…
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) — Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today…
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv,…
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
The conference will stream live on Monday, June 12, at 10:00 AM EST Tel Aviv,…
Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission
– Pure-Vu Gastro achieves high usability scores in supporting upper endoscopy procedures with first time…
Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission
– Pure-Vu Gastro achieves high usability scores in supporting upper endoscopy procedures with first time…
Shockwave Appoints Kevin Ballinger to Board of Directors
SANTA CLARA, Calif., May 17, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a…
Shockwave Appoints Kevin Ballinger to Board of Directors
SANTA CLARA, Calif., May 17, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a…
ORYZON to Present Trial in Progress Phase Ib FRIDA Study at the Upcoming 2023 ASCO Annual Meeting
MADRID, Spain and BOSTON, May 17, 2023 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code:…
ORYZON to Present Trial in Progress Phase Ib FRIDA Study at the Upcoming 2023 ASCO Annual Meeting
MADRID, Spain and BOSTON, May 17, 2023 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code:…
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful…
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer
Media Release Immuno-oncology combination of eftilagimod alpha (efti) and the leading anti-PD-1 therapy generates meaningful…
Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank
Refinanced Loan Extends Maturity to December 2024 SEATTLE and VANCOUVER, British Columbia, May 17, 2023…